VER
Vascular & Endovascular Review

Future Trends in Vascular Research: Translational Advances in Atherosclerosis Diagnosis and Treatment

Rakesh Patel[1], Shivani Khoware[1], Nikita Tomar[1], Richa Jadhav[1], Shantanu Naik[1], Aryan Patel[1], Priyanshi Pandey[1], Ishan Dubey*[1]

[1]Department of Pharmacy, Malwa Institute of Pharmaceutical Sciences, Indore, M.P., India

***Author for Correspondence:**
Dr Ishan Dubey, Professor, Department of Pharmacy, Malwa Institute of Pharmaceutical Sciences, Indore, M.P., India

ABSTRACT

Atherosclerosis remains a principal cause of cardiovascular morbidity and mortality worldwide. Although significant progress has been made in understanding lipid metabolism, inflammation, and plaque biology, existing diagnostic and therapeutic strategies have limitations in predicting events and reversing advanced lesions. Rapid advances in molecular biology, multiomics, bioengineering, regenerative medicine, imaging, and artificial intelligence have transformed the translational landscape of vascular research. This review highlights emerging trends in atherosclerosis research, including genomics-driven risk prediction, molecular imaging, nanotechnology-based drug delivery, targeted immunomodulatory therapies, endothelial restoration strategies, and AI-guided decision support systems. These innovations promise earlier detection, sustained plaque stabilization, and personalized therapy.

How to Cite: Rakesh Patel, Shivani Khoware, Nikita Tomar1, Richa Jadhav, Shantanu Naik, Aryan Patel, Priyanshi Pandey, Ishan Dubey, (2025) Future Trends in Vascular Research: Translational Advances in Atherosclerosis Diagnosis and Treatment, Vascular and Endovascular Review, Vol.8, No.16s, 349-355.

INTRODUCTION

Atherosclerosis is a chronic, progressive vascular disease characterized by the accumulation of lipids, inflammatory cells, and fibrous components within the arterial wall, ultimately forming atherosclerotic plaques. The pathological process is initiated by endothelial dysfunction, often triggered by modifiable risk factors such as hypertension, smoking, diabetes, and elevated low-density lipoprotein (LDL) cholesterol. These factors impair endothelial integrity, increasing vascular permeability to lipoproteins and promoting local inflammation (Gusev et al., 2023). Once LDL particles infiltrate the intima, they undergo oxidative modification, triggering the recruitment of immune cells—particularly monocytes and macrophages. These macrophages internalize oxidized LDL and transform into foam cells, leading to the formation of fatty streaks, the earliest detectable lesions of atherosclerosis. As the disease advances, complex interactions among vascular smooth muscle cells, inflammatory mediators, and extracellular matrix components promote plaque maturation, characterized by fibrous cap formation, necrotic core development, and progressive calcification (Dushkin, 2012).

Atherosclerotic plaques may remain stable for long periods or transition into vulnerable forms prone to rupture. **Plaque rupture**, followed by thrombus formation, can critically obstruct blood flow, leading to acute clinical events such as myocardial infarction, ischemic stroke, or peripheral arterial occlusion. Because atherosclerosis primarily affects medium- and large-sized arteries and progresses silently over decades, early detection and preventive strategies remain essential.

Current management emphasizes lifestyle modifications and pharmacological interventions, including lipid-lowering agents such as statins, which reduce cardiovascular risk by stabilizing plaques and lowering LDL-C levels. Emerging therapies targeting inflammatory pathways, oxidative stress, and lipid metabolism reflect evolving insights into plaque biology (Poznyak et al., 2022).
Looking ahead, vascular research is shifting rapidly toward **precision medicine**, emphasizing early risk prediction, molecular profiling of plaques, and personalized treatment strategies. Innovations in genomics, advanced imaging, nanomedicine, and regenerative vascular repair offer promising avenues for improving early diagnosis and enhancing therapeutic outcomes. This review examines key translational advancements shaping the future of atherosclerosis diagnosis and treatment.



Figure 1: Schematic of Atherosclerosis Development

MULTIOMICS APPROACHES IN ATHEROSCLEROSIS

2.1 Genomics and Polygenic Risk Scores

Genome-wide association studies (GWAS) have identified more than 250 genetic loci associated with CAD (Nikpay et al., 2015). Polygenic risk scores (PRS) aggregate these variants to estimate an individual's inherited risk. PRS predicts CAD even in young adults before clinical risk factors emerge, enabling early interventions (Inouye et al., 2018).

Applications include:

- Early statin therapy in genetically susceptible individuals
- Identification of high-risk but asymptomatic populations
- Integration with lifestyle modification programs

PRS will likely become a standard part of preventive cardiology as sequencing costs decrease.

2.2 Transcriptomics and Single-Cell RNA Sequencing (scRNA-seq)

scRNA-seq has revealed heterogeneity within endothelial cells, macrophages, and smooth muscle cells (SMCs), uncovering phenotypic switching during plaque progression (Fernandez et al., 2019). Novel discoveries include:

- SMCs transdifferentiating into macrophage-like cells
- Inflammatory fibroblast subsets driving plaque instability
- Endothelial-to-mesenchymal transition (EndMT) in vulnerable plaques

These findings provide potential therapeutic targets such as KLF4-mediated SMC modulation.

2.3 Proteomics and Metabolomics

Advanced proteomics identifies circulating proteins linked to plaque instability, such as matrix metalloproteinases (MMPs), VCAM-1, and myeloperoxidase (MPO) (Zhang et al., 2021). Metabolomic signatures—including trimethylamine-N-oxide (TMAO) and ceramides—predict adverse cardiovascular outcomes (Wang et al., 2021). Future clinical use includes developing personalized biomarker panels combining lipid, inflammatory, and metabolomic markers.



Figure 2: Multiomics Approaches in Atherosclerosis

ADVANCEMENTS IN IMAGING TECHNOLOGIES

The early and accurate detection of atherosclerotic plaque vulnerability remains one of the most critical objectives in modern cardiovascular research. While conventional imaging methods—such as coronary angiography and standard CT—are highly effective in assessing luminal stenosis, they fall short in identifying the biological activity of plaques, particularly inflammation, microcalcification, and fibrous cap instability (Rudd et al., 2019). Therefore, next-generation imaging focuses not only on structural abnormalities but also on functional and molecular characteristics that determine plaque behavior. This shift enables earlier diagnosis, improved risk prediction, and more precise monitoring of therapeutic response.

3.1 Molecular Imaging

3.1.1 Positron Emission Tomography (PET)

Molecular imaging using PET tracers has become a powerful tool for visualizing inflammation and mineral metabolism within plaques.

18F-FDG PET: Imaging Macrophage Metabolism

18F-fluorodeoxyglucose (18F-FDG) is a glucose analogue taken up by metabolically active cells, notably macrophages within inflamed plaques.

- Increased uptake correlates with macrophage density, an established marker of plaque vulnerability (Tarkin et al., 2017).
- 18F-FDG PET has been used to monitor the anti-inflammatory effects of statins and novel immunomodulators.

18F-NaF PET: Detecting Microcalcification

18F-sodium fluoride (18F-NaF) selectively binds to hydroxyapatite surfaces, allowing detection of:

- Active microcalcification
- Osteogenic activity
- Sites of plaque instability

18F-NaF PET is particularly valuable because microcalcification precedes larger calcified deposits and is associated with plaque rupture risk (Joshi et al., 2014). This tracer has shown promise in predicting future cardiovascular events by identifying "hotspots" of calcific inflammation.

PET/MRI Fusion

Hybrid PET/MRI integrates metabolic information from PET with high-resolution soft tissue imaging from MRI.

- Enhances visualization of fibrous caps, necrotic cores, and intraplaque hemorrhage.
- Reduces radiation exposure compared to PET/CT.

3.1.2 Targeted Nanoparticle Contrast Agents

Nanotechnology-enabled contrast agents allow plaque visualization at the molecular level. These nanoparticles can be functionalized to bind specific biomarkers such as:

- Oxidized LDL (oxLDL)
- Macrophage scavenger receptors (SR-A1, CD36)
- VCAM-1, an endothelial adhesion molecule upregulated during inflammation
- MMPs, involved in fibrous cap degradation

Examples include iron oxide nanoparticles for MRI and gold nanoparticles for CT imaging (Mulder et al., 2021). These agents enable:

- Early detection of subclinical inflammation
- Tracking of therapeutic response
- Visualization of plaque biology before structural changes occur

3.2 High-Resolution MRI and CT Innovations

3.2.1 Photon-Counting Computed Tomography (PCCT)

Photon-counting CT represents a major step forward in vascular imaging. Unlike conventional CT detectors, which measure cumulative energy, PCCT counts individual photons and assesses their energy levels. Advantages include:

- Higher spatial resolution—enables detailed visualization of plaque calcification and fibrous structures
- Improved contrast-to-noise ratio
- Reduced radiation exposure
- Enhanced detection of low-attenuation (lipid-rich) plaques (Rajendran et al., 2022).

3.2.2 Ultra-Short Echo Time (UTE) MRI

Conventional MRI sequences cannot visualize calcification due to rapid signal decay. UTE MRI, with echo times in the microsecond range, makes previously "invisible" plaque components detectable.

UTE MRI advantages:

- Clear visualization of calcified plaques, which typically appear dark in standard MRI
- Detection of fibrous caps, collagen-rich regions, and lipid pools
- No radiation exposure

3.3 Intravascular Imaging

Intravascular imaging techniques provide detailed visualization from within the vessel lumen, enabling near-histological assessment of plaque morphology.

3.3.1 Optical Coherence Tomography (OCT)

OCT uses near-infrared light to achieve extremely high axial resolution (~10–20 µm).
It is capable of:

- Measuring fibrous cap thickness
- Identifying microchannels, cholesterol clefts, and intraplaque hemorrhage
- Differentiating between stable and vulnerable plaques

3.3.2 Intravascular Ultrasound (IVUS) and IVUS-NIRS Hybrids

IVUS provides deeper penetration than OCT, making it ideal for assessing:

- Overall plaque burden
- Vessel remodeling
- Calcification

Near-infrared spectroscopy (NIRS) complements IVUS by detecting lipid-core plaques.
The combined IVUS-NIRS modality provides both structural and compositional information, allowing precise quantification of:

- Lipid core burden index (LCBI)
- Plaque vulnerability scores

3.3.3 AI-Enhanced Intravascular Imaging

Artificial intelligence (AI) is increasingly applied to intravascular imaging to automate plaque assessment.
AI can:

- Detect plaque features such as lipid arcs, cap thickness, and calcification patterns
- Predict risk of rupture using machine learning models trained on OCT/IVUS datasets
- Reduce inter-observer variability
- Integrate multimodal intravascular data (O'Brien et al., 2022)



Figure 3: Advancements in Imaging Technologies

ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN ATHEROSCLEROSIS

4.1 AI-Driven Predictive Models

Machine learning integrates clinical variables, imaging, and biomarkers to predict cardiovascular events with higher accuracy than traditional risk scores (Khera et al., 2019). AI systems can detect subtle plaque features from CT angiography, predicting stenosis progression.

4.2 Automated Imaging Interpretation

Deep learning enables:

- Automated quantification of plaque burden
- Identification of high-risk plaque morphology
- Detection of endothelial shear stress zones that promote plaque formation

NANOMEDICINE AND TARGETED DRUG DELIVERY

Nanotechnology improves drug delivery by enhancing bioavailability, reducing systemic toxicity, and allowing targeted therapy.

5.1 Lipid-Based Nanoparticles

Lipid nanoparticles (LNPs) can deliver statins, anti-inflammatory drugs, or siRNA directly to plaques.

5.2 Polymer-Based Nanocarriers

Polymers such as PLGA can encapsulate hydrophobic drugs, releasing them slowly. Targeting ligands (antibodies, peptides) allow plaque-specific delivery (Zhou et al., 2020).

5.3 Biomimetic Nanoparticles

Cell membrane-coated nanoparticles (e.g., macrophage- or platelet-derived) evade immune detection and home to inflamed plaques.



Figure 4: Nanomedicine and Targeted Drug Delivery

IMMUNOMODULATORY AND ANTI-INFLAMMATORY THERAPIES

Inflammation drives plaque progression, making it a key therapeutic target.

6.1 Interleukin Pathway Targeting

- CANTOS trial showed IL-1β inhibition reduced recurrent cardiovascular events (Ridker et al., 2017).
- IL-6 inhibitors are emerging targets.

6.2 Inflammasome Inhibition

NLRP3 inflammasome inhibitors such as MCC950 are under investigation to suppress plaque inflammation at the molecular level.

6.3 Chemokine and Adhesion Molecule Targeting

Blocking MCP-1/CCR2, VCAM-1, or ICAM-1 may reduce macrophage recruitment and plaque inflammation.

GENE THERAPY AND GENE EDITING

CRISPR-Cas9 technologies open new avenues for lipid regulation.

7.1 PCSK9 Gene Editing

CRISPR-mediated PCSK9 disruption shows long-term LDL lowering in animal models (Musunuru et al., 2021).

7.2 Apo(a) and Lipoprotein(a) Targeting

Antisense oligonucleotides targeting Lp(a) reduce levels by up to 80% (Tsimikas et al., 2020), offering hope for patients with genetically elevated Lp(a).

7.3 Smooth Muscle Cell Reprogramming

Gene therapies aim to maintain SMC stability and prevent phenotype switching, reducing plaque vulnerability.

REGENERATIVE AND ENDOTHELIAL RESTORATION THERAPIES

8.1 Endothelial Progenitor Cells (EPCs)

EPC transplantation improves endothelial repair and suppresses atherosclerotic progression (Sen et al., 2021).

8.2 Extracellular Vesicle (EV)-Based Therapy

EVs derived from stem cells carry microRNAs that restore endothelial integrity, reduce inflammation, and inhibit SMC migration.

8.3 Tissue-Engineered Vascular Grafts

Biomaterials seeded with stem cells support vascular regeneration and may replace bypass grafts in future interventions.

GUT MICROBIOME MODULATION

Gut-derived metabolites such as TMAO contribute to plaque formation. Strategies include:

- Probiotics and prebiotics
- Enzyme inhibitors that block TMAO formation
- Fecal microbiota transplantation (FMT) research

Microbiome-targeted therapies may complement traditional lipid-based treatments.

DISCUSSION

Atherosclerosis research is rapidly evolving from structural assessment and broad-spectrum therapies to molecularly targeted diagnostics and treatments. Multiomics systems reveal underlying mechanisms, while AI and molecular imaging improve prediction accuracy. Nanotechnology, gene editing, and immunomodulation offer possibilities for long-term disease modification. Integrating these innovations into clinical practice requires large-scale trials, cost-effectiveness studies, and ethical frameworks, especially for gene editing and AI-driven tools.

CONCLUSION

Future vascular research is transitioning from reactive care to proactive, predictive, and personalized therapy. Translational advances—ranging from genomics to nanomedicine—are poised to transform atherosclerosis management, enabling earlier diagnosis, targeted interventions, and ultimately plaque regression. Continued interdisciplinary collaboration will drive these innovations into routine clinical practice.

Table 1. Emerging Technologies in Atherosclerosis Research

Technology	Application	Current Status
Polygenic Risk Scores	Early genetic risk detection	Clinical integration in progress
PET/MRI Molecular Imaging	Detect inflammation & calcification	Advanced clinical trials
AI-Driven CT Analysis	Automated plaque risk scoring	Widespread clinical adoption
Nanoparticle Drug Delivery	Targeted therapy to plaques	Preclinical to early clinical
CRISPR PCSK9 Editing	Long-term LDL reduction	Early human trials
Stem Cell–Derived EVs	Endothelial repair	Preclinical research



Figure 5. Future Translational Approaches

REFERENCES

1. Dushkin, M. I. (2012). Macrophage/foam cell is an attribute of inflammation: mechanisms of formation and functional role. *Biochemistry (Moscow)*, *77*(4), 327-338.
2. Fernandez, D. M., et al. (2019). Single-cell analysis of atherosclerosis reveals dynamic endothelial and immune cell interactions. *Nature Medicine, 25*(10), 1576–1588.
3. Gusev, E., & Sarapultsev, A. (2023). Atherosclerosis and inflammation: insights from the theory of general pathological processes. *International Journal of Molecular Sciences*, *24*(9), 7910.
4. Inouye, M., et al. (2018). Genomic risk prediction of coronary artery disease in 480,000 adults. *Journal of the American College of Cardiology, 72*(16), 1883–1893.
5. Joshi, N. V., et al. (2014). 18F-NaF PET identifies active calcification in coronary arteries. *JACC: Cardiovascular Imaging, 7*(4), 349–357.
6. Joshi, N. V., Vesey, A. T., Williams, M. C., Shah, A. S., Calvert, P. A., Craighead, F. H., ... & Dweck, M. R. (2014). *18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial.* The Lancet, 383(9918), 705–713.
7. Khera, R., et al. (2019). Machine learning for risk prediction in cardiovascular disease. *Circulation Research, 124*(12), 1793–1798.
8. Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., Tokgözoğlu, L., & Lewis, E. F. (2019). Atherosclerosis. *Nature Reviews Disease Primers, 5*(56), 1–18.
9. Mulder, W. J. M., Jaffer, F. A., Fayad, Z. A., & Nahrendorf, M. (2021). *Imaging and nanomedicine in inflammatory atherosclerosis.* Science Translational Medicine, 13(577), eabd5359.
10. Musunuru, K., et al. (2021). In vivo gene editing for PCSK9 inhibition. *Circulation, 143*(5), 549–556.
11. Nikpay, M., et al. (2015). GWAS meta-analysis of coronary artery disease. *Nature Genetics*, *47*(10), 1121–1130.
12. O'Brien, C., Villiger, M., Lami, H., et al. (2022). *Artificial intelligence for vulnerable plaque detection using intravascular imaging.* JACC: Cardiovascular Imaging, 15(1), 78–92.
13. O'Brien, E. C., et al. (2022). Artificial intelligence and intravascular imaging. *European Heart Journal*, *43*(12), 1101–1112.
14. Poznyak, A. V., Sadykhov, N. K., Kartuesov, A. G., Borisov, E. E., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2022). Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment. *Frontiers in cardiovascular medicine*, *9*, 959285.
15. Rajendran, K., et al. (2022). *Photon-counting CT in cardiovascular imaging: technological principles and clinical applications.* Radiology, 304(3), 550–565.
16. Ridker, P. M., & Libby, P. (2023). Residual inflammatory risk. *European Heart Journal*, *44*(3), 182–195.
17. Ridker, P. M., et al. (2017). Antiinflammatory therapy with canakinumab. *New England Journal of Medicine*, *377*(12), 1119–1131.
18. Rudd, J. H., Hyafil, F., Fayad, Z. A. (2019). *Inflammation imaging in atherosclerosis.* Circulation Research, 124(3), 437–453.
19. Sen, S., et al. (2021). Endothelial progenitor cell therapy for vascular repair. *Stem Cell Research & Therapy, 12*, 1–12.
20. Tarkin, J. M., et al. (2017). *Imaging atherosclerosis inflammation with FDG PET.* JACC: Cardiovascular Imaging, 10(11), 1200–1212.
21. Tsimikas, S., et al. (2020). Antisense therapy for lipoprotein(a) reduction. *New England Journal of Medicine, 382*(3), 244–255.
22. Wang, Z., et al. (2021). TMAO and cardiovascular disease. *Nature Reviews Cardiology, 18*(7), 473–483.
23. Zhang, Y., et al. (2021). Proteomics in atherosclerosis. *Atherosclerosis, 331*, 1–10.
24. Zhou, J., et al. (2020). Nanomedicine for atherosclerosis. *Advanced Drug Delivery Reviews, 159*, 140–151.